Literature DB >> 10421037

Epidemiology of bacterial infection during management of open leg fractures.

H Carsenti-Etesse1, F Doyon, N Desplaces, O Gagey, C Tancrède, C Pradier, B Dunais, P Dellamonica.   

Abstract

In a randomised double-blind trial conducted between 1990 and 1994, 616 patients from 43 centres, pefloxacin (group P, 316 patients) and a cefazolin-oxacillin combination (group C, 300 patients) were compared in the prophylaxis of bone infection after grade 1 and 2 open leg fractures. Samples were obtained at emergency, before and during surgery, and from drain aspirates. Antimicrobial susceptibility, slime production and adherence properties of the bacteria were tested. Cultures at emergency and before surgery showed similar distributions of gram-positive and gram-negative bacteria in both groups, while wound closure and infecting isolates showed prevailing gram-positive bacteria in group P and gram-negative bacteria in group C. Positive cultures at each stage were correlated with the occurrence of infection but were not predictive of the infecting species, which were nosocomial bacteria in most cases. Positive cultures at wound closure warn of a higher infection risk. Twenty-one of 316 (6.6%) patients in group P and 24 of 300 (8%) in group C were considered infected within 3 months. The difference is not significant (chi-square test = 0.42; P = 0.51). Infecting strains were isolated from 38 patients (group P, 18; group C, 20). Infecting species, although not predictable, appear to be those escaping the spectrum of the prescribed antimicrobial prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10421037     DOI: 10.1007/pl00015012

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  26 in total

1.  [Therapy of chronic osteomyelitis: soft tissues as "key to success"].

Authors:  R M Sellei; P Kobbe; M Knobe; P Lichte; T Dienstknecht; S W Lemmen; H-C Pape
Journal:  Orthopade       Date:  2012-01       Impact factor: 1.087

2.  [Conductive bone substitute material with variable antibiotic delivery].

Authors:  C Englert; P Angele; J Fierlbeck; S Dendorfer; T Schubert; R Müller; S Lienhard; J Zellner; M Nerlich; C Neumann
Journal:  Unfallchirurg       Date:  2007-05       Impact factor: 1.000

3.  Extremity and Orthopaedic Injuries.

Authors:  V K Sinha; S Anand
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  [Fractures of the extremities with severe open soft tissue damage. Initial management and reconstructive treatment strategies].

Authors:  P Schwabe; N P Haas; K D Schaser
Journal:  Unfallchirurg       Date:  2010-08       Impact factor: 1.000

5.  What is the rate of methicillin-resistant Staphylococcus aureus and Gram-negative infections in open fractures?

Authors:  Antonia F Chen; Verena M Schreiber; Wesley Washington; Nalini Rao; Andrew R Evans
Journal:  Clin Orthop Relat Res       Date:  2013-10       Impact factor: 4.176

Review 6.  Negative pressure wound therapy in grade IIIB tibial fractures: fewer infections and fewer flap procedures?

Authors:  Daniel R Schlatterer; Adam G Hirschfeld; Lawrence X Webb
Journal:  Clin Orthop Relat Res       Date:  2015-01-17       Impact factor: 4.176

Review 7.  [Primary soft tissue management in open fracture].

Authors:  F Riechelmann; P Kaiser; R Arora
Journal:  Oper Orthop Traumatol       Date:  2018-09-04       Impact factor: 1.154

8.  Local Injection of Aminoglycosides for Prophylaxis Against Infection in Open Fractures.

Authors:  Cheryl Reese Lawing; Feng-Chang Lin; Laurence E Dahners
Journal:  J Bone Joint Surg Am       Date:  2015-11-18       Impact factor: 5.284

Review 9.  The evidence base for 2017 BOAST-4 guidance on open fracture management: Are we due an update?

Authors:  Yahya Ibrahim; Shazil Jamal; Kashif Akhtar
Journal:  J Clin Orthop Trauma       Date:  2021-04-01

10.  Treatment principles in the management of open fractures.

Authors:  William W Cross; Marc F Swiontkowski
Journal:  Indian J Orthop       Date:  2008-10       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.